MedTrace Logo

Positron Emission Tomography in Determining Stage of Esophageal Cancer

NCT00004867 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 235

Last updated 2017-01-24

No results posted yet for this study

Summary

RATIONALE: Imaging procedures such as positron emission tomography may improve the ability to determine the stage of esophageal cancer.

PURPOSE: This clinical trial is studying how well fludeoxyglucose F 18 positron emission tomography determines tumor stage in patients with esophageal cancer.

Conditions

  • Esophageal Cancer

Interventions

PROCEDURE

conventional surgery

PROCEDURE

positron emission tomography

PROCEDURE

radionuclide imaging

RADIATION

fludeoxyglucose F 18

DRUG

chemotherapy

RADIATION

Radiotherapy

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • Alliance for Clinical Trials in Oncology

    lead OTHER

Principal Investigators

  • Bryan F. Meyers, MD, MPH · Washington University Siteman Cancer Center

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1999-11-30
Primary Completion
2005-07-31
Completion
2009-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00004867 on ClinicalTrials.gov